Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
by
Cheng, Ting
, Wang, Yongpeng
, Yuan, Dexiao
, Cao, Zhihua
, Wang, Fang
in
Acute Coronary Syndrome - diagnostic imaging
/ Acute Coronary Syndrome - drug therapy
/ Acute Coronary Syndrome - pathology
/ Atherosclerosis
/ Cholesterol
/ Cholesterol, LDL - blood
/ Coronary Artery Disease - diagnostic imaging
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - pathology
/ Coronary vessels
/ Coronary Vessels - diagnostic imaging
/ Coronary Vessels - drug effects
/ Coronary Vessels - pathology
/ Drug Therapy, Combination
/ High density lipoprotein
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Lipoproteins
/ Meta-Analysis and Systematic Review
/ Multimodal Imaging
/ PCSK9 Inhibitors
/ Plaque, Atherosclerotic - diagnostic imaging
/ Plaque, Atherosclerotic - drug therapy
/ Plaque, Atherosclerotic - pathology
/ Proprotein Convertase 9 - metabolism
/ Statins
/ Tomography
/ Treatment Outcome
/ Ultrasonography, Interventional
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
by
Cheng, Ting
, Wang, Yongpeng
, Yuan, Dexiao
, Cao, Zhihua
, Wang, Fang
in
Acute Coronary Syndrome - diagnostic imaging
/ Acute Coronary Syndrome - drug therapy
/ Acute Coronary Syndrome - pathology
/ Atherosclerosis
/ Cholesterol
/ Cholesterol, LDL - blood
/ Coronary Artery Disease - diagnostic imaging
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - pathology
/ Coronary vessels
/ Coronary Vessels - diagnostic imaging
/ Coronary Vessels - drug effects
/ Coronary Vessels - pathology
/ Drug Therapy, Combination
/ High density lipoprotein
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Lipoproteins
/ Meta-Analysis and Systematic Review
/ Multimodal Imaging
/ PCSK9 Inhibitors
/ Plaque, Atherosclerotic - diagnostic imaging
/ Plaque, Atherosclerotic - drug therapy
/ Plaque, Atherosclerotic - pathology
/ Proprotein Convertase 9 - metabolism
/ Statins
/ Tomography
/ Treatment Outcome
/ Ultrasonography, Interventional
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
by
Cheng, Ting
, Wang, Yongpeng
, Yuan, Dexiao
, Cao, Zhihua
, Wang, Fang
in
Acute Coronary Syndrome - diagnostic imaging
/ Acute Coronary Syndrome - drug therapy
/ Acute Coronary Syndrome - pathology
/ Atherosclerosis
/ Cholesterol
/ Cholesterol, LDL - blood
/ Coronary Artery Disease - diagnostic imaging
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - pathology
/ Coronary vessels
/ Coronary Vessels - diagnostic imaging
/ Coronary Vessels - drug effects
/ Coronary Vessels - pathology
/ Drug Therapy, Combination
/ High density lipoprotein
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Lipoproteins
/ Meta-Analysis and Systematic Review
/ Multimodal Imaging
/ PCSK9 Inhibitors
/ Plaque, Atherosclerotic - diagnostic imaging
/ Plaque, Atherosclerotic - drug therapy
/ Plaque, Atherosclerotic - pathology
/ Proprotein Convertase 9 - metabolism
/ Statins
/ Tomography
/ Treatment Outcome
/ Ultrasonography, Interventional
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
Journal Article
Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Background
Statins are the standard treatment for coronary atherosclerosis; however, some patients require additional therapies for optimal plaque regression. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i), including monoclonal antibodies and small interfering RNA-based therapies, have shown promise as adjuncts to statins, although their efficacy for coronary plaque regression, as assessed by intravascular imaging, remains uncertain.
Methods
We conducted a meta-analysis to compare the treatment efficacy of statins combined with PCSK9i (PCSK9i group) versus statins alone or statins combined with placebo (control group) in adults with coronary atherosclerosis (INPLASY registration number: INPLASY202550027). Plaque lesions were assessed using intravascular ultrasound, optical coherence tomography, coronary computed tomography angiography, and near-infrared spectroscopy. Lipid profile parameters, including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and lipoprotein(a), were measured and analyzed.
Results
In total, 11 trials involving 2490 patients (follow-up duration: 12–78 weeks) were included. Meta-regression showed that combination therapy significantly reversed coronary artery plaque (p < 0.001). No significant difference was observed in the atheroma volume between the PCSK9i and control groups; however, fibrous cap thickness increased significantly in the PCSK9i group. Additionally, low-density lipoprotein cholesterol and lipoprotein(a) levels decreased, while high-density lipoprotein cholesterol levels increased after PCSK9i treatment.
Conclusion
PCSK9i combined with statins effectively promote coronary plaque regression, particularly in patients with acute myocardial infarction, offering a promising approach for managing coronary atherosclerosis.
Publisher
SAGE Publications,Sage Publications Ltd,SAGE Publishing
Subject
Acute Coronary Syndrome - diagnostic imaging
/ Acute Coronary Syndrome - drug therapy
/ Acute Coronary Syndrome - pathology
/ Coronary Artery Disease - diagnostic imaging
/ Coronary Artery Disease - drug therapy
/ Coronary Artery Disease - pathology
/ Coronary Vessels - diagnostic imaging
/ Coronary Vessels - drug effects
/ Coronary Vessels - pathology
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Meta-Analysis and Systematic Review
/ Plaque, Atherosclerotic - diagnostic imaging
/ Plaque, Atherosclerotic - drug therapy
/ Plaque, Atherosclerotic - pathology
/ Proprotein Convertase 9 - metabolism
/ Statins
This website uses cookies to ensure you get the best experience on our website.